This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (91)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Rachel S. Eidelman, MD; Patricia R. Hebert, PhD; Steven M. Weisman, PhD; Charles H. Hennekens, MD, DrPH

Arch Intern Med. 2003;163:2006-2010.

Background  In 1988, the aspirin component of the Physicians' Health Study, a randomized, double-blind, placebo-controlled trial of 22 071 apparently healthy men was terminated early, due principally to a statistically extreme (P<.00001) 44% reduction in the risk of a first myocardial infarction (MI). The Cardio-Renal Drugs Advisory Committee recommended that the US Food and Drug Administration approve professional labeling of aspirin to prevent first MI. The agency did not act on this recommendation because the only other trial, the British Doctors' Trial of 5139 men, showed no significant benefits. Since that time, 3 additional randomized trials (which included men and women) of aspirin in the primary prevention of MI have been published.

Methods  A computerized search of the English literature from 1988 to the present revealed 5 published trials: the Physicians' Health Study (22 071 participants), the British Doctors' Trial (5139), the Thrombosis Prevention Trial (5085), the Hypertension Optimal Treatment Study (18 790), and the Primary Prevention Project (4495).

Results  Among the 55 580 randomized participants (11 466 women), aspirin was associated with a statistically significant 32% reduction in the risk of a first MI and a significant 15% reduction in the risk of all important vascular events, but had no significant effects on nonfatal stroke or vascular death.

Conclusions  The current totality of evidence provides strong support for the initial finding from the Physicians' Health Study that aspirin reduces the risk of a first MI. For apparently healthy individuals whose 10-year risk of a first coronary event is 10% or greater, according to the US Preventive Services Task Force and the American Heart Association, the benefits of long-term aspirin therapy are likely to outweigh any risks.

From the Division of Cardiovascular Research, Mount Sinai Medical Center–Miami Heart Institute, Miami Beach, Fla (Drs Eidelman and Hennekens); Department of Internal Medicine (Cardiology), Yale University School of Medicine, New Haven, Conn (Dr Hebert); Innovative Science Solutions, Morristown, NJ (Dr Weisman); and Departments of Medicine & Epidemiology and Public Health, University of Miami School of Medicine, Miami, Fla (Dr Hennekens). Dr Eidelman receives grants from Bayer and Pfizer. Dr Hennekens receives grants from Bayer and serves as consultant to Astra-Zeneca, Bayer, Bristol-Myers Squibb, Chattem, DelacoGlaxo-SmithKline, McNeil, Novartis, Pfizer, and Reliant. Dr Weisman serves as a consultant to Bayer, GlaxoSmithKline, Pharmacia, and Boehringer-Ingelheim.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Accelerated atherosclerosis in systemic lupus erythematosus: perspectives towards decreasing cardiovascular morbidity and mortality
Escarcega et al.
Lupus 2009;18:383-386.
 

The Role of Aspirin in Cardiovascular Disease Prevention in Women
Hopkins and Limacher
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2009;3:123-134.
ABSTRACT  

Aspirin for the Chemoprevention of Colorectal Adenomas: Meta-analysis of the Randomized Trials
Cole et al.
JNCI J Natl Cancer Inst 2009;101:256-266.
ABSTRACT | FULL TEXT  

Age threshold for vascular prophylaxis by aspirin in patients without diabetes
Bulugahapitiya et al.
Heart 2008;94:1429-1432.
ABSTRACT | FULL TEXT  

Newly Appreciated Pathophysiology of Ischemic Heart Disease in Women Mandates Changes in Perioperative Management: A Core Review
Matyal
Anesth. Analg. 2008;107:37-50.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Aspirin Treatment in the Primary Prevention of Cardiovascular Disease Events in Subgroups Based on Age, Gender, and Varying Cardiovascular Risk
Greving et al.
Circulation 2008;117:2875-2883.
ABSTRACT | FULL TEXT  

The Role of Aspirin in Cardiovascular Prevention: Implications of Aspirin Resistance
Gasparyan et al.
J Am Coll Cardiol 2008;51:1829-1843.
ABSTRACT | FULL TEXT  

A health economic evaluation of concomitant surgical ablation for atrial fibrillation
Lamotte et al.
Eur. J. Cardiothorac. Surg. 2007;32:702-710.
ABSTRACT | FULL TEXT  

Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition
Klein et al.
Cardiovasc Res 2007;75:390-397.
ABSTRACT | FULL TEXT  

Can Aspirin Keep Mortality at Bay?
Baron
Arch Intern Med 2007;167:535-536.
FULL TEXT  

Effects of tomato extract on platelet function: a double-blinded crossover study in healthy humans.
O'Kennedy et al.
Am. J. Clin. Nutr. 2006;84:561-569.
ABSTRACT | FULL TEXT  

Dose of Aspirin in the Treatment and Prevention of Cardiovascular Disease: Current and Future Directions.
Hennekens et al.
J CARDIOVASC PHARMACOL THER 2006;11:170-176.
ABSTRACT  

Increased systolic blood pressure with rofecoxib in congenital furosemide-like salt loss
Komhoff et al.
Nephrol Dial Transplant 2006;21:1833-1837.
ABSTRACT | FULL TEXT  

Aspirin and clopidogrel resistance: an emerging clinical entity
Wang et al.
Eur Heart J 2006;27:647-654.
ABSTRACT | FULL TEXT  

Aspirin for the Primary Prevention of Cardiovascular Events in Women and Men: A Sex-Specific Meta-analysis of Randomized Controlled Trials
Berger et al.
JAMA 2006;295:306-313.
ABSTRACT | FULL TEXT  

Cyclooxygenase-1 Deficiency in Bone Marrow Cells Increases Early Atherosclerosis in Apolipoprotein E- and Low-Density Lipoprotein Receptor-Null Mice
Babaev et al.
Circulation 2006;113:108-117.
ABSTRACT | FULL TEXT  

Risk of Hemorrhagic Stroke With Aspirin Use: An Update
Gorelick and Weisman
Stroke 2005;36:1801-1807.
ABSTRACT | FULL TEXT  

ASHP Therapeutic Position Statement on the Daily Use of Aspirin for Preventing Cardiovascular Events
Saseen
Am J Health Syst Pharm 2005;62:1398-1405.
FULL TEXT  

JournalScan
Malik
Heart 2005;91:847-848.
FULL TEXT  

A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker et al.
NEJM 2005;352:1293-1304.
ABSTRACT | FULL TEXT  

Concurrent Treatment With Renin-Angiotensin System Blockers and Acetylsalicylic Acid Reduces Nuclear Factor {kappa}B Activation and C-Reactive Protein Expression in Human Carotid Artery Plaques
Sattler et al.
Stroke 2005;36:14-20.
ABSTRACT | FULL TEXT  

Aspirin Use Among Adults With Diabetes: Recent Trends and Emerging Sex Disparities
Persell and Baker
Arch Intern Med 2004;164:2492-2499.
ABSTRACT | FULL TEXT  

President's page: The promise of prevention: So, why aren't all cardiologists "preventive"?
Wolk et al.
J Am Coll Cardiol 2004;44:2082-2084.
FULL TEXT  

Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance
Cattaneo
Arterioscler. Thromb. Vasc. Bio. 2004;24:1980-1987.
ABSTRACT | FULL TEXT  

Therapeutic options for patients with chronic myocardial ischaemia
Serruys and Aoki
Eur Heart J Suppl 2004;6:E2-E11.
ABSTRACT | FULL TEXT  

Throw Away the Aspirin and Take Nonsteroidal Anti-Inflammatory Drugs for the Primary Prevention of Myocardial Infarction * Response
Eliasziw et al.
Circulation 2004;109 :e65-e66.
FULL TEXT  

JournalScan
Malik
Heart 2003;89:1467-1468.
FULL TEXT